{"commentary":{"count":210,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":89,"youtube":84,"podcast":37},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03319667\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMROZ","nct_id":"NCT03319667","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imroz-nct03319667. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"IMROZ","arms":[{"description":"1. Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone\n2. Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone","label":"Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm","type":"EXPERIMENTAL"},{"description":"1. Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone\n2. Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone","label":"Bortezomib/Lenalidomide/Dexamethasone = VRd arm","type":"ACTIVE_COMPARATOR"},{"description":"4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone","label":"Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm","type":"OTHER"}],"collaborators":[],"completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"conditions":["Plasma Cell Myeloma"],"enrollment":{"count":475,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Isatuximab SAR650984","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2026-05-04","lead_sponsor":"Sanofi","official_title":"A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-04-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"Up to approximately 100 months after the First Participant In (FPI)"}],"references":[{"citation":"Orlowski RZ, Dimopoulos MA, Leleu X, Facon T, Ishida T, Hajek R, Spicka I, Romejko-Jarosinska J, Vorobyev V, Besemer B, Besisik SK, Robak P, Jelinek T, Goldschmidt H, Martin T, Mohty M, Mace S, Kodas E, Tekle C, Shafer AT, Moreau P. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study. Blood. 2026 Jun 4;147(23):2760-2769. doi: 10.1182/blood.2025030120.","pmid":"41758929","type":"DERIVED"},{"citation":"Manier S, Dimopoulos MA, Leleu XP, Moreau P, Cavo M, Goldschmidt H, Orlowski RZ, Tron M, Tekle C, Bregeault MF, Shafer AT, Beksac M, Facon T. Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. Haematologica. 2025 Sep 1;110(9):2139-2150. doi: 10.3324/haematol.2024.287200. Epub 2025 Mar 20.","pmid":"40109195","type":"DERIVED"},{"citation":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hajek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Bregeault MF, Mace S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3.","pmid":"38832972","type":"DERIVED"},{"citation":"Thoren K, Menad S, Nouadje G, Mace S. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma. J Appl Lab Med. 2024 Jul 1;9(4):661-671. doi: 10.1093/jalm/jfae028.","pmid":"38573925","type":"DERIVED"}],"start_date":{"date":"2017-12-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","url":"https://clinicaltrials.gov/study/NCT03319667"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imroz-nct03319667"}